Scientists at Southern University of Science and Technology in Shenzhen, China, have identified a new regulator of the mammalian target of rapamycin (mTOR) pathway associated with the growth of ...

Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA highlighting the role of exosomal RNA (exRNA) in head and neck cancers (HNCs).

Our research group is interested in understanding, at the structural and mechanistic levels, the maintenance of genomic integrity and the control of cell growth, both of which figure prominently in ...

Too much mTOR has been linked to cancer. Biodexa said the dosing given to cohort 2 – daily every other week – will likely be the preferred dosage regime for its phase 3 trial, which the ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

It examines the impact of mTOR on podocytes ... gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies ...

Everolimus (Afinitor) is a drug that blocks the mTOR protein and helps stop the growth and spread of cancer cells. PI3K inhibitors. Alpelisib (Piqray) and inavolisib (Itovebi) block a type of ...

Konstantinopoulos, MD, PhD, of the Dana-Farber Cancer Institute in Boston ... activated protein kinase], leading to inhibition of mTOR signalling, and indirectly by decreasing circulating insulin ...

and mTOR all relieve feedback, but the details of their effects differ, which suggests why these drugs vary in their in efficacy and toxicity. This work has enhanced our understanding of the oncogenic ...